| Inactivated |
Easy to prepare; proven technology; safety; multivalent; no adjuvants required; induce strong immune responses |
Potential inappropriate for persons with immunosuppression; complicated to scale up manufacturing |
Polio |
| Live-Attenuated |
Rapid development; proven technology; multivalent; no adjuvants required; induce strong immune responses |
Possibility of reversion; risk for infection; complicated to scale up manufacturing |
Measles, Mumps, Rubella, Chickenpox |
| Subunit |
Safety; consistent production; induce strong cellular and humoral immune responses |
High cost; lower immunogenicity; require repeated doses and adjuvants; complicated to scale up manufacturing |
Pertussis, Hepatitis B, Influenza |
| Viral Vector-Based |
Safety; induces strong cellular and humoral responses |
Potential risk for infection, chromosomal integration and oncogenesis; possibly present pre-existing immunity against the vector; risk for inflammatory adverse reactions |
Ebola |
| RNA |
Safety; rapid development and production; no risk of genetic integration; possibility of multivalency; induce strong immune responses, both humoral and cell-mediated |
Unstable under physiological conditions; possibility of inflammatory reactions; risk for adverse reactions; high cost |
Not currently licensed |
| DNA |
Safety; rapid development and production; possibility of multivalency; immune response, both humoral and cell-mediated; long-term stability; possibility of oral formulation |
Poor immune responses in humans; repeated doses may cause toxicity; potential risk of genetic integation |
Not currently licensed |
